SIGA

SIGA Technologies, Inc. [SIGA] Stock Forecast

Q: What is SIGA Technologies, Inc. stock symbol ?

SIGA Technologies, Inc. is a US stock, located in New york of Ny and trading under the symbol SIGA

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

SIGA Stock Summary

Earnings have grown 26.31% per last year.

Earnings are expected to rise 21.03% next year

EPS has been increasing for the past 3 quarters (Quarter statements)

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Profit margins (-0.14%) are lower than the previous year (0.49%)

SIGA has less than 1 year of cash runway

Top 10 Correlated ETFs

SIGA

Top 10 Correlated Stocks

SIGA

In the News

06:56 16 Apr 2024 SIGA

Siga Technologies Inc. (SIGA) Advances While Market Declines: Some Information for Investors

Siga Technologies Inc. (SIGA) reachead $8.88 at the closing of the latest trading day, reflecting a +0.79% change compared to its last close.

11:01 16 Apr 2024 SIGA

Best Momentum Stocks to Buy for April 12th

SIGA, SEIC and NTRS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 12, 2024.

08:32 16 Apr 2024 SIGA

New Strong Buy Stocks for April 12th

ZUO, INTZ, SIGA, ENVB and NTRS have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2024.

07:36 16 Apr 2024 SIGA

Best Value Stocks to Buy for April 12th

SIGA and AZZ made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 12, 2024.

11:01 16 Apr 2024 SIGA

Best Momentum Stocks to Buy for April 10th

DELL, AGRO and SIGA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 10, 2023.

07:46 16 Apr 2024 SIGA

New Strong Buy Stocks for April 10th

DELL, WEAV, AGRO, SIGA and STEP have been added to the Zacks Rank #1 (Strong Buy) List on April 10, 2023.

11:01 16 Apr 2024 SIGA

Best Momentum Stocks to Buy for April 2nd

HITI, MPC and SIGA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 2, 2023.

08:06 16 Apr 2024 SIGA

New Strong Buy Stocks for April 2nd

CXDO, HITI, SIGA, CPG and CTKB have been added to the Zacks Rank #1 (Strong Buy) List on April 2, 2023.

02:46 16 Apr 2024 SIGA

Siga Technologies: Preparing For A Contingency If Tomorrow Comes

01:01 16 Apr 2024 SIGA

All You Need to Know About Siga Technologies (SIGA) Rating Upgrade to Buy

Siga Technologies (SIGA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SIGA Financial details

Company Rating

Strong Buy

Market Cap

626.32M

Income

68.07M

Revenue

139.92M

Book val./share

2.77

Cash/share

2.11

Dividend

0.45

Dividend %

8.46%

Employees

Optionable

Shortable

Yes

Earnings

01 Mar 2024

P/E

-75.66

Forward P/E

8.07

PEG

-6.94

P/S

10.87

P/B

3.05

P/C

4.21

P/FCF

49.37

Quick Ratio

2.57

Current Ratio

4.75

Debt / Equity

LT Debt / Equity

EPS (TTM)

0.96

EPS next Y

1.1

EPS next Q

EPS this Y

106.52%

EPS next Y

14.42%

EPS next 5Y

14.42%

EPS last 5Y

NAN%

Revenue last 5Y

39.23%

Revenue Q/Q

1161.27%

EPS Q/Q

-18645.45%

SMA20

53.27%

SMA50

84.85%

SMA100

82.63%

Inst Own

44.81%

Inst Trans

0.98%

ROA

-3%

ROE

-3%

ROC

-0.08%

Gross Margin

31%

Oper. Margin

-28%

Profit Margin

-14%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

4.22-10.0

52W High

-11.2%

52W Low

+122%

RSI

60.97

Rel Volume

1.23

Avg Volume

753.93K

Volume

924K

Perf Week

-1%

Perf Month

70.44%

Perf Quarter

72.09%

Perf Half Y

63.24%

Beta

0.969

Volatility

0.17%, 1.67%

Prev Close

0.79%

Price

8.88

Change

-3.48%

SIGA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.33	1.58	1.77	1.52	1.96
Net income per share	-0.09	0.71	0.92	0.46	0.95
Operating cash flow per share	-0.22	0.9	0.15	0.57	1.33
Free cash flow per share	-0.23	0.9	0.15	0.57	1.33
Cash per share	0.81	1.49	1.37	1.35	2.1
Book value per share	1.21	1.64	2.31	2.33	2.76
Tangible book value per share	1.2	1.63	2.3	2.32	2.75
Share holders equity per share	1.21	1.64	2.31	2.33	2.76
Interest debt per share	1.19	0.04	0.01	-0.01	0.01
Market cap	386.52M	576.21M	566.42M	536.76M	399.63M
Enterprise value	401.73M	458.77M	463.75M	438.5M	250.95M
P/E ratio	-53.38	10.23	8.16	15.83	5.87
Price to sales ratio	14.45	4.61	4.24	4.85	2.86
POCF ratio	-21.23	8.06	49.28	12.9	4.22
PFCF ratio	-21.2	8.06	49.5	12.9	4.22
P/B Ratio	3.95	4.44	3.25	3.15	2.03
PTB ratio	3.95	4.44	3.25	3.15	2.03
EV to sales	15.02	3.67	3.47	3.96	1.79
Enterprise value over EBITDA	391.14	5.36	5.17	10.03	2.98
EV to operating cash flow	-22.07	6.41	40.34	10.54	2.65
EV to free cash flow	-22.03	6.42	40.52	10.54	2.65
Earnings yield	-0.02	0.1	0.12	0.06	0.17
Free cash flow yield	-0.05	0.12	0.02	0.08	0.24
Debt to equity	0.82	0	0	0	0
Debt to assets	0.41	0	0	0	0
Net debt to EBITDA	14.81	-1.37	-1.14	-2.25	-1.77
Current ratio	1.96	13.7	6.85	8.63	4.42
Interest coverage	0.03	28.01	0	-46.5	0
Income quality	2.51	1.27	0.17	1.23	1.39
Dividend Yield	0	0	0	0.06	0.08
Payout ratio	0	0	0	0.97	0.47
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.5	0.09	0.07	0.22	0.12
Intangibles to total assets	0	0.01	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-0.06	-0.03	-0.1	0	-0.04
Stock based compensation to revenue	0.08	0.01	0.01	0.02	0.01
Graham number	1.56	5.12	6.93	4.94	7.69
ROIC	0	0.5	0.4	0.19	0.33
Return on tangible assets	-0.04	0.38	0.32	0.17	0.27
Graham Net	-0.34	1.39	1.8	1.75	1.96
Working capital	88.31M	133.12M	178.27M	164.27M	184.87M
Tangible asset value	96.89M	128.89M	173.42M	169.26M	195.96M
Net current asset value	79.26M	123.57M	168.34M	160.91M	181.01M
Invested capital	0.82	0	0	0	0
Average receivables	3.06M	3.75M	43.5M	64.53M	33.27M
Average payables	2.37M	2.17M	1.65M	2.69M	2.41M
Average inventory	6.28M	14.96M	19.89M	29.39M	51.75M
Days sales outstanding	56.89	9.76	228.42	149.61	55.12
Days payables outstanding	73.89	18.13	27.89	37.16	29.82
Days of inventory on hand	233.55	287.41	268.28	434.94	1.31K
Receivables turnover	6.42	37.41	1.6	2.44	6.62
Payables turnover	4.94	20.13	13.09	9.82	12.24
Inventory turnover	1.56	1.27	1.36	0.84	0.28
ROE	-0.07	0.43	0.4	0.2	0.35
Capex per share	0	0	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.16	0.12	0.08	0.13	1.64
Net income per share	-0.01	-0.01	-0.04	-0.01	1.02
Operating cash flow per share	-0.11	0.34	-0.05	-0.07	1.11
Free cash flow per share	-0.11	0.34	-0.05	-0.07	1.11
Cash per share	1.36	1.6	1.07	1	2.11
Book value per share	2.34	2.25	1.75	1.75	2.77
Tangible book value per share	2.33	2.23	1.73	1.73	2.76
Share holders equity per share	2.34	2.25	1.75	1.75	2.77
Interest debt per share	0.02	0	0.01	0.01	0.01
Market cap	535.08M	415.13M	359.01M	373.19M	398.11M
Enterprise value	436.81M	299.99M	283.34M	302.64M	249.43M
P/E ratio	-164.78	-113.02	-31.21	-237.36	1.38
Price to sales ratio	47.11	49.88	61.07	40.41	3.42
POCF ratio	-66.01	16.98	-100.28	-73.18	5.04
PFCF ratio	-66.01	16.98	-99.67	-73.18	5.04
P/B Ratio	3.14	2.56	2.89	3.01	2.02
PTB ratio	3.14	2.56	2.89	3.01	2.02
EV to sales	38.46	36.04	48.2	32.77	2.14
Enterprise value over EBITDA	-1.81K	-151.73	-61.09	-257.93	2.72
EV to operating cash flow	-53.89	12.27	-79.14	-59.35	3.16
EV to free cash flow	-53.89	12.27	-78.67	-59.35	3.16
Earnings yield	0	0	-0.01	0	0.18
Free cash flow yield	-0.02	0.06	-0.01	-0.01	0.2
Debt to equity	0	0	0	0	0
Debt to assets	0	0	0	0	0
Net debt to EBITDA	407.85	58.24	16.31	60.14	-1.62
Current ratio	8.63	9.34	7.07	4.75	4.42
Interest coverage	-2.39	2.37	0	0	0
Income quality	9.99	-26.62	1.25	12.97	1.09
Dividend Yield	0	0	0.09	0	0
Payout ratio	0	0	-11.18	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	1.41	0.31	0.79	0.14	0.02
Intangibles to total assets	0	0	0.01	0.01	0
Capex to operating cash flow	0	0	0.01	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	-0.16	0	0
Stock based compensation to revenue	0.06	0.05	0.12	0.05	0
Graham number	0.77	0.8	1.26	0.47	7.96
ROIC	-0.01	-0.01	-0.03	-0.01	0.36
Return on tangible assets	0	-0.01	-0.02	0	0.28
Graham Net	1.76	1.72	1.18	1.06	1.97
Working capital	164.27M	154.06M	115.31M	115.23M	184.87M
Tangible asset value	169.26M	161.2M	123.18M	123.24M	195.96M
Net current asset value	160.91M	150.7M	111.86M	111.73M	181.01M
Invested capital	0	0	0	0	0
Average receivables	50.17M	28.86M	9.17M	7.04M	14.59M
Average payables	2.9M	2.25M	1.11M	822.8K	1.01M
Average inventory	35.27M	40.93M	46.54M	57.72M	64.58M
Days sales outstanding	359.8	133.19	92.28	78.45	16.33
Days payables outstanding	41.44	16.56	15.98	11.17	8.85
Days of inventory on hand	485.04	618.44	746.19	1.29K	390.41
Receivables turnover	0.25	0.68	0.98	1.15	5.51
Payables turnover	2.17	5.44	5.63	8.05	10.17
Inventory turnover	0.19	0.15	0.12	0.07	0.23
ROE	0	-0.01	-0.02	0	0.37
Capex per share	0	0	0	0	0

SIGA Dividend History

SIGA Frequently Asked Questions

What is SIGA Technologies, Inc. stock symbol ?

SIGA Technologies, Inc. is a US stock , located in New york of Ny and trading under the symbol SIGA

What is SIGA Technologies, Inc. stock quote today ?

SIGA Technologies, Inc. stock price is $8.88 today.

Is SIGA Technologies, Inc. stock public?

Yes, SIGA Technologies, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 753.93K
Market Capitalization 626.32M
Employee 45
CEO Dr. Diem Nguyen M.B.A., Ph.D.
Headquarters New York,NY,US
IPO Date 1997-09-10
Website https://www.siga.com

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.